Nubratori, Inc., Torrance, CA

Is Nubratori, Inc. an FDA-registered 503B outsourcing facility?

Yes. FDA’s registered outsourcing facility list, updated Nov 6, 2026, names Nubratori, Inc. in Torrance, CA, first registered Feb 24, 2017 and most recently registered Nov 5, 2026. FDA lists its last inspection as Dec 11, 2025, with a Form FDA 483 issued; FDA lists the action on that inspection as “Response Letter Issued 4/29/2026; Warning Letter Closeout Issued 7/27/2026; FMD-145 Issued 7/21/2026”.

FDA registers outsourcing facilities under section 503B; state boards of pharmacy issue pharmacy licenses separately. FDA’s list does not say which drugs a facility makes.

Location on FDA’s list
Torrance, CA
Initial registration
Feb 24, 2017
Most recent registration
Nov 5, 2026
Last inspection
Dec 11, 2025
Form 483 issued at last inspection
Yes
Recall after last inspection
No
Action on last inspection
Response Letter Issued 4/29/2026; Warning Letter Closeout Issued 7/27/2026; FMD-145 Issued 7/21/2026
Intends to compound sterile drugs from bulk substances
Yes

FDA inspections and actions on record

FDA’s compounding inspections and actions page (current as of Oct 22, 2026) lists this facility as Nubratori Inc. dba Nubratori Rx, Torrance, CA, a 503B facility, with 7 listed actions, including 3 Form 483s and 1 warning letter (2019 to 2025).

Document
Dec 11, 2025Form 483483 Issued 12/11/2025fda.gov
Jan 22, 2025Warning letterWarning Letter Issued 01/22/2025FDA copy (archived)
Jul 26, 2024Form 483483 Issued 07/26/2024FDA copy (archived)
May 6, 2022FMD-145 letterFMD-145 Letter Issued 05/06/2022Not linked by FDA
Sep 21, 2021FMD-145 letterFMD-145 Letter Issued 09/21/2021Not linked by FDA
Sep 26, 2019Form 483483 Issued 09/26/2019FDA copy (archived)
May 15, 2019FMD-145 letterFMD-145 Letter Issued 05/15/2019fda.gov

A Form 483 lists investigator observations, not a final FDA determination. A warning letter states FDA’s view when it was issued, not a court finding; any close-out letter FDA lists is a row of its own. An untitled or FMD-145 letter states FDA’s view when it was issued.

Matched to the 503B list by city, state and the exact legal name with the same legal ending. Check the heading above against the facility you are looking for.

FDA inspection classifications and published Form 483s

The FDA Data Dashboard, read Nov 15, 2026, lists Nubratori, Inc, Torrance, CA (FEI number 3010166491), matched to this page by exact name, city and state. It lists 5 inspections: 1 OAI, 2 VAI, 2 NAI at that site, newest first, with FDA’s classification as worded on the dashboard. Dashboard firm profile.

Inspection endedClassificationProject area and product typeFEIInspection ID
Dec 11, 2025Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30101664911294878
Jul 26, 2024Official Action Indicated (OAI)Drug Quality Assurance (Drugs)30101664911244125
Dec 20, 2021No Action Indicated (NAI)Drug Quality Assurance (Drugs)30101664911160434
Sep 26, 2019Voluntary Action Indicated (VAI)Drug Quality Assurance (Drugs)30101664911102948
Apr 10, 2018No Action Indicated (NAI)Drug Quality Assurance (Drugs)30101664911049260

Form 483s FDA has published for this site

FDA classifies each inspection when it is closed: No Action Indicated (NAI) means no objectionable conditions were found or they did not justify further action; Voluntary Action Indicated (VAI) means objectionable conditions were found but FDA is not prepared to take or recommend regulatory action; Official Action Indicated (OAI) means FDA recommended regulatory or administrative action. A classification is FDA’s, not a finding by this site. The dashboard lists inspections once FDA has classified them, from fiscal year 2009 on, so a recent inspection may not appear yet.

Form 483 observations

A Form 483 lists an FDA investigator’s observations at the end of an inspection. It is not a final FDA determination. In FDA’s words: “The FDA Form 483 does not constitute a final Agency determination of whether any condition is in violation of the FD&C Act or any of its relevant regulations.” (FDA Form 483 FAQ). The firm may have answered or corrected these points; a response is not shown here unless FDA lists one.

FDA’s published Form 483s for this site have 13 numbered observations in all, across 3 inspections ending Sep 26, 2019 to Dec 11, 2025. Each observation is quoted from the PDF as FDA numbered it, with long ones cut and linked to the full form. Names of people on the form are not shown. What a Form 483 is; all 483s in this index.

Inspection Dec 1, 2025 to Dec 11, 2025: 3 observations

Firm on the cover
Nubratori, Inc, 381 Van Ness Ave Ste 1507, Torrance, CA 90501-7220
FEI number
3010166491
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, 503B list, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Written procedures are not established for the cleaning and maintenance of equipment, including utensils, used in the manufacture, processing, packing or holding of a drug product.

Specifically,

a. Cleaning validation studies conducted in 2017 relied on media fill activities as a surrogate rather than using residues from actual drug products. Sampling after a media fill does not represent worst-case cleaning conditions for therapeutic compounds and does not demonstrate the effectiveness of the cleaning process in removing active pharmaceutical ingredient (API) residues generated dming routine production.

b. Cleaning validation studies conducted in 2017 selected <Redacted B4> non-sterile <Redacted B4> as the worst-case product without adequate scientific justification relative to all the sterile injectable drug products manufactured at the facility. Yow-fnm did not appropriately evaluate relevant worst-case factors such as therapeutic potency, solubility characteristics, toxicological properties, and cleaning difficulty of shared equipment, etc. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Your firm failed to establish adequate written procedures for production and process controls designed to assure that the drug products have the identity, strength, purity, and quality that they are purported or represented to possess.

Specifically,

a. Failure to Complete Process Validation for Modified Manufacturing Process: In 2023, your firm changed the vial filling configuration for Lidocidex I (Dexamethasone Sodium Phosphate/Lidocaine HCl Injection, 3.33 mg/mL; 6.67 mg/mL) from using <Redacted B4> without performing appropriate process validation studies. Similar vial filling changes were made to Lidomar-Lidocaine HCl/Bupivacaine HCl Injection; (10 mg/1 mL; 3.75 mg/1 mL). Your risk assessment dated 05/01/2023 failed to systematically evaluate critical risks including sterility assurance, filling dynamics, process parameters affecting product quality, and modified aseptic manipulation techniques. This significant process change requires comprehensive process validation to demonstrate that the modified procedure consistently produces drug products meeting predetermined specifications and quality attributes. ...

Read the full 483 (PDF on fda.gov)

Observation 3

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile are not established and written.

Specifically:

a. Your 2024 smoke studies do not include simulated set-up of environmental monitoring (EM) plates within the hood to demonstrate that EM preparation activities and plate placement do not compromise unidirectional airflow patterns or create turbulence that could introduce contamination to the critical zone. During my observation of the compounding of Lidocidex I (Dexamethasone Phosphate with Lidocaine HCl (3.33mg/6.67mg/ml), Lot C12032501 , I observed personnel preparing EM samples inside the ISO 1:/ laminar airflow hood (LAFH) prior to compounding operations, including opening EM plate packaging and labeling plates with non­sterile markers. These activities introduced unnecessaiy particulate and microbial contamination risks and disrupted unidirectional airflow essential for maintaining sterility. Your procedures fail to define appropriate locations for EM preparation activities, resulting in uncontrolled introduction of non-sterile items into the ISO <Redacted B4> environment.

b. ...

Read the full 483 (PDF on fda.gov)

Inspection Jul 16, 2024 to Jul 26, 2024: 7 observations

Firm on the cover
Nubratori, Inc, 381 Van Ness Ave Ste 1507, Torrance, CA 90501-7220
FEI number
3010166491
Establishment type on the cover
Outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contamination of drug products purporting to be sterile did not include adequate validation of the aseptic process.

Specifically,

A. You do not perfo1m growth promotion studies on media used during Media Fills. Your fnm uses <Redacted B4> and <Redacted B4> for your Media Fills and therefore does not have evidence that the media can promote the growth of gram-positive, gram-negative bacteria, yeast, and mold.

B. Your firm has not performed product validation for Dexamethasone 24 mg/ml Injectable, Preservative Free using the final distributed container. During normal production, your firm uses 2mL amber vials, however, all product validation studies and media fills have used 2 mL <Redacted B4> vials. Dexamethasone 24 mg/ml Injectable is a light sensitive compound.

C. Media fill batch records do not reflect all manipulations performed during normal production.

Your firm includes the use <Redacted B4> however this <Redacted B4>is not used in any of the <Redacted B4> sterilized, aseptically filled sterile products. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Aseptic processing areas are deficient regarding the system for monitoring environmental conditions.

Specifically,

On 07/17/2024, during the production of Lidocaine HCl/Tetracaine HCl (Lot# <Redacted B4> I observed a technician collect their glove fingertip personnel monitoring samples, after wiping a piece of air sampling equipment with Sterile <Redacted B4>, and samples were not taken immediately after completion of aseptic operations. Personnel momtonng samples should be taken before planned disinfection. The technicians did not follow the order listed in the Batch Production Record for sampling.

Observation 3

Aseptic processing areas are deficient regarding the system for cleaning and disinfecting the room and equipment to produce aseptic conditions.

Specifically,

On 07/17/2024, during the production of Lidocaine HCl/Tetracaine HCl (Lot# <Redacted B4>. I observed that the operator failed to wipe down the ISO 7 side of the <Redacted B4> with stenle <Redacted B4> before opening it to receive materials from the ISO 8 ante room. I observed the operator failed to clean the legs of the ISO 5 <Redacted B4>air flow hood before aseptic operations.

Observation 4

Acceptance criteria for the sampling and testing conducted by the quality control unit is not adequate to assure that batches of drug products meet each appropriate specification and appropriate statistical quality control criteria as a condition for their approval and release.

Specifically,

Your firm's visual inspection program is inadequate.

a. You do not document the complete results of the <Redacted B4> acceptance rate inspection performed by Quality control after the 100% visual inspection and instead use a stamp to denote approval.

b. Your firm failed to demonstrate that operators can adequately identify defects with the use of <Redacted B4>during the visual inspection of amber vials. Products filled in amber vials include Dexamethasone Sodium Phosphate Injection and Dexamethasone Sodium Phosphate/Lidocaine HCl Injection.

c. You failed to establish a minimum time for the inspection of each vial against the <Redacted B4> backgrounds.

d. You firm's defect kit is deficient. The library of defects used to qualify visual inspectors is composed of <Redacted B4> of which contain multiple defects in each vial. ...

Read the full 483 (PDF on fda.gov)

Observation 5

Each lot of a component liable to objectionable microbiological contamination is deficiently subjected to microbiological tests before use.

Specifically,

Acceptance of incoming lots of non-sterile component for use in sterile drug products must include microbial and endotoxin testing and meet limits appropriate for the drug product's intended use. Your firm failed to perform microbial and endotoxin testing on all lots of the following Bulk Drug Substances (BDS):

• Dexamethasone Sodium Phosphate

• Lidocaine

• Tetracaine HCl

These BDS were used to compound the following sterile finished products:

• Dexamethasone Sodium Phosphate 24 mg/ml Injectable, Preservative Free, Lot 5# <Redacted B4> BUD 01/19/2025

• 0.4% Lidocaine HCl with 0.2% Tetracaine HCl Injection, Preservative Free, Lot #5 <Redacted B4> BUD 03/14/2025

Observation 6

Establishment of the reliability of the component supplier's report of analyses is deficient in that the test results are not appropriately validated at appropriate intervals.

Specifically,

Your firm failed to conduct full testing as part of the Bulk Drug Substance <Redacted B4> re-qualification of supplier qualification. Your firm's written procedure is inadequate as section 5 .1.4 states ,<Redacted B4.>. Your firm has not performed full testing of incoming raw materials from its BDS supplier, since 2019, which applies to the following BDS:

• Dexamethasone Sodium Phosphate (Lot <Redacted B4>).

• Lidocaine HCl (Lot <Redacted B4>)

• Tetracaine HCl (Lot <Redacted B4>)

• Baclofen (Lot <Redacted B4>) • Diclofenac Sodium (Lot <Redacted B4>) • Gabapentin (Lot # <Redacted B4>) • Ketamine HCl (Lot <Redacted B4>) • Ketoprofen (Lot <Redacted B4>) • Naltrexone (Lot <Redacted B4>)

Observation 7

Your outsourcing facility has not submitted a report to FDA identifying a product compounded during the previous six months as required by section 503B(b)(2)(A) of the Federal Food, Drng, and Cosmetic Act (FD&C Act).

Specifically,

The following product was compounded and not identified on your repo1i dated December 2022.

• Diclofenac Sodium 40 mg/2.5 g (16 mg/lg) Topical Gel, 2.5 Grams Single Use Unit

Inspection Aug 26, 2019 to Sep 26, 2019: 3 observations

Firm on the cover
Nubratori, Inc dba Nubratori Rx, 381 Va n Ness Ave Ste 1507, Torrance, CA 90501-7220
FEI number
3010166491
Establishment type on the cover
outsourcing Facility
FDA district office on the cover
19701 Fairchild Irvine, CA 92612-2445
Matched to this page by
FEI number on the cover; linked from actions page, Data Dashboard
FDA document
Read the full 483 (PDF on fda.gov)

Observation 1

Procedures designed to prevent microbiological contaminati on of drug products purporting to be sterile are not established.

Specifically,

A) Your firm's most recent smoke study video, filmed on 6/28/2019 of in situ air pattern analysis, was not conducted under dynamic conditions that simulate routine production, such as <Redacted B4> , IV have manipulation and injection of drug product into multiple sealed, sterile SmL clear vials, with <Redacted B4> Without simulating unidirectional airflow and its sweeping action over and away from a representative operation within the laminar <Redacted B4> aidlow hood, there is no assurance critical processing areas are suitable for aseptic manufacturing of sterile drug products.

B) On 8/28/19, I observed your compounding technician allow vials and tubing lines to be positioned into the path of unidirectional "first air" during the vial filling process ofLidocaine HCI w/Bupivacaine HCl Injection USP, Lot No. C08281901.

C) On 9/24/19, I observed your compotmding technician allow gloved hand and vial to be positioned into the path of first air during the vial filling process of Lidocidex 5mg/10mgfl.5m L Injection, Lot No. CO9241901. ...

Read the full 483 (PDF on fda.gov)

Observation 2

Disinfectant contact time (also known as "dwell time") and coverage of the item being disinfected were insufficient to achieve adequate levels of disinfection.

Specifically,

The <Redacted B4> dwell time of your <Redacted B4> neither recorded in a cleaning record nor correctly identified within your <Redacted B4> Cleaning Procedure of Cleanroom, SOP 4.13.

Observation 3

You compound drugs that are essentially a copy of one or more approved drugs within the meaning of sections 503B(a)(5) and 503B(d)(2). Specifically, you compound drug products that: are not identical or nearly identical to an approved drug, but contain a bulk drug substance that is also a component of an approved drug, and for which there is no change that produces for an individual patient a clinical difference, as determined by the prescribing practitioner, between the compounded drug and the comparable approved drug.

Examples of compounded drug products that are essentially a copy of one or more approved drugs include:

IFE-PG20 (alprostadil injection)

GLP-1 records in this index

No FDA warning letter or recall report naming a GLP-1 drug in this index, as of Nov 15, 2026, is addressed to this facility’s exact legal name (Nubratori, Inc.). That is not a finding beyond this index’s search.

The Nubratori, Inc. pharmacy page answers whether it has had a state board action or FDA letter, from the same FDA lists.

This page lists public regulatory records as published by the issuing agency. A record is not a finding by this site. A warning letter states the agency’s view at the time it was issued; companies may have responded or corrected the issue since. Follow each link for the original document and any close-out letter. Report an error or add a company response.

Sources

Records last pulled Nov 15, 2026. Every entry links to the original public record.